Synopsis：Tigecycline is a new broad-spectrum intravenous antibiotic, which belongs to 9-tert-butylglycamide minocycline derivative. It is the first glycylcycline antibiotic. Although its structure is similar to minocycline, the change of its molecular structure not only greatly improves its antibacterial activity, but also makes it less resistant to other tetracycline drugs than other tetracycline drugs, and also has activity against methicillin-resistant Staphylococcus aureus. The mechanism of tigecycline is similar to that of tetracycline antibiotics. Tigecycline binds with 30S ribosome of bacteria to prevent the entry of transferred RNA, which makes amino acids unable to bind to form peptide chains. In the end, tigecycline plays a role in blocking bacterial protein synthesis and limiting bacterial growth. The antibacterial spectrum of tigecycline includes Gram-positive bacteria, Gram-negative bacteria and anaerobic bacteria.
Structural formula:
Properties
Summary
Tigecycline is a new broad-spectrum intravenous antibiotic, which belongs to 9-tert-butylglycamide minocycline derivative. It is the first glycylcycline antibiotic. Although its structure is similar to minocycline, the change of its molecular structure not only greatly improves its antibacterial activity, but also makes it less resistant to other tetracycline drugs than other tetracycline drugs, and also has activity against methicillin-resistant Staphylococcus aureus. The mechanism of tigecycline is similar to that of tetracycline antibiotics. Tigecycline binds with 30S ribosome of bacteria to prevent the entry of transferred RNA, which makes amino acids unable to bind to form peptide chains. In the end, tigecycline plays a role in blocking bacterial protein synthesis and limiting bacterial growth. The antibacterial spectrum of tigecycline includes Gram-positive bacteria, Gram-negative bacteria and anaerobic bacteria.
Manufacturing
